Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo probiótico para veterinaria

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORS20151222001
Publicado:
11/01/2016
Caducidad:
11/01/2017
Resumen:
Una spin-off serbia dispone de licencia exclusiva limitada para la producción, venta y distribución de un nuevo probiótico que se emplea en la prevención y tratamiento de infecciones intestinales causadas por bacterias difíciles de curar en mamíferos, desarrollado por un instituto científico. La ventaja frente a otros probióticos es el uso de bacterias seguras. La empresa ha demostrado con ensayos preclínicos que este cultivo probiótico tiene propiedades inmunomoduladoras únicas y una actividad antimicrobiana específica contra un gran número de cepas bacterianas patógenas. La empresa está interesada en establecer acuerdos de financiación, joint venture y licencia.

Details

Tittle:
Innovative probiotic for animal use
Summary:
A Serbian spin-off company has limited exclusive license for production, sale and distribution of innovative probiotic for prevention and treatment of hardly curable bacterial gut infections in mammals, developed by the scientific institute. Advantages over existing probiotics are usage of safe bacteria in composition of probiotics and probiotic potential.
The company is interested in financial, joint venture and license agreement.
Description:
A Serbian spin-off company has been founded with goal of production, sale and distribution of the innovative probiotic that is highly effective in treatment of fastidious gut infections of different etiology with wide antimicrobial spectrum for various pathogens. The company has been owned by innovators of the probiotic with years of experience and knowledge in the fields of molecular microbiology, veterinary practice, specifically in farm animals, who set the requirements for this innovation and designed this innovative probiotic. In addition, the company staff has experience in management and their direct contacts with future customers are crucial for the initial distribution of the products. The company staff has also experience in the field of microbiology, technology, food and design of starters and it was crucial for the selection of natural isolates that have entered into the composition of the innovative probiotic culture, as well as for the development of the technological process for its preparation.
Based on preclinical tests, as well as on the basis of farm trials, the company has shown that this innovative probiotic culture has unique immunomodulatory properties as well as the specific antimicrobial activity against a large number of pathogenic bacterial strains. It appeared that this innovative probiotic culture, in contrast to conventional probiotics, may be used as an alternative to use of antibiotics in treatment of intestinal infections, especially in the case of fastidious and hardly curable infections. The novel probiotic culture has been developed during the innovation project financed by the Ministry of Education, Science and Technological Development Republic of Serbia, in 2013-2015.
The company is interested in finding partners for licensing agreement. The company provides limited exclusive license for the production and distribution of probiotics for animals for 10 years (with an obligation of extension of the license agreement if the partner fulfills its part of the contract).
The company is interested also in finding partners for financial agreement in term of investments or joint venture agreement in exchange for percent of share, where the company will produce and distribute the probiotic in Western Balkan region.
Advantages and Innovations:
The advantage over existing technical solutions is that this probiotic culture consists exclusively of lactic acid bacteria (LAB), with generally recognized as safe status and specific probiotic potential. Due to safe composition the innovative probiotic culture can be also used for pregnant animals. It increases the immune status of the animal, and the acquired immunity is transmitted to the offspring that are therefore healthier comparing to the controls. Currently available probiotics for animals in Serbia and Western Balkans region are sold in the form of dry feed supplemented with probiotics. In such products the number and survival of probiotic bacteria are not reproducible, bacteria are not metabolically active, and they need some time for activation.
The innovative probiotic is a liquid fermented probiotic product, in which probiotic bacteria are metabolically active, the number and survival of bacteria in the product is stable, and their probiotic effects exhibit immediately upon arrival in the intestine. Probiotic product is scalable and prepared in dosages recommended for animals for which it was designed.
The novelty compared to the state of the art is that this probiotic culture has a much broader antimicrobial spectrum of existing probiotics and has specific antimicrobial activity against pathogenic bacteria such as Clostridium sp. and exerts specific immunomodulatory effect. In combination with antimicrobial activity this immunomodulatory activity enables its use in the prevention and treatment of hardly curable infections for which there is no known effective treatment and could be successfully used as replacement for antibiotics.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
The bacteria that are part of the innovative probiotic culture are deposited in the bacterial international collection of the University of Ghent, under patent protection, and a patent application was submitted to Intellectual Property Office of the Republic of Serbia in December 2015.
The company has a limited exclusive license for the production and distribution of probiotic culture for animals for 10 years (with an obligation of extension of the license agreement if the company fulfills its part defined in license agreement) for Serbia, Croatia, Bosnia and Herzegovina, Montenegro, Hungary and Romania.

Partner sought

Type and Role of Partner Sought:
Type: Industry

Activity: Companies which are in business of production and distribution of probiotics for animals, companies interested in financing in probiotic industry.

Role: In licence agreement, it is expected from the partner to distribute the probiotic globally.
In financial agreement, it is expected from the partner to invest in scale up in exchange for percent of share.
In joint venture agreement, it is expected from the partner to have experience in global sale and distribution.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Serbian

Keywords

Technology Keywords:
08001002 Aditivos / ingredientes alimentarios / alimentos funcionales
07001009 Medicina veterinaria
06002008 Microbiología